Cell therapy for hard-to-treat lupus (REACT-01)
Part of Immune system & allergy, Skin clinical trials.
This trial tests a new type of cell therapy (CAR T-cells) to see if it can stop the immune system from attacking the body in severe lupus. It’s for people ages 2–30 whose lupus is not controlled by other treatments and who are willing to be treated at Seattle Children’s Hospital.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 2 to 30 years old (first few patients must be 17 or older).
- Active lupus that has not responded to standard treatments.
- Able to undergo a blood cell collection procedure (apheresis) or have a stored product ready.
- No recent use of certain lupus medications: at least 24 weeks since Rituximab, 12 weeks since Benlysta or Anifrolumab, and 4 weeks since calcineurin inhibitors.
- No active infections, brain involvement from lupus, or need for dialysis.
- Live within 1 hour of Seattle Children’s Hospital for 4 weeks after the CAR T cell infusion.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of cell therapy (CAR-T cells) that targets two proteins on immune cells (CD19 and BCMA) to treat lupus that hasn't responded to standard treatments. It may help people with moderate to severe lupus by reducing disease activity without ongoing medication.
This trial tests a new CAR-T cell treatment for people with lupus who still have moderate to severe symptoms despite trying standard medications. It aims to quickly stop the immune system from attacking the body.
This trial tests a new type of cell therapy, called BCMA/CD70 CAR-T, for children with lupus that hasn't improved with standard treatments. The goal is to see if it can safely reduce disease activity.
This trial tests a new cell therapy (RJMty19) for people with lupus that hasn't improved with standard treatments. It aims to reduce disease activity and may help those with active organ involvement.
This trial tests a quick-made CAR-T cell therapy for children and adults with active lupus who haven't gotten better with standard drugs. The goal is to see if targeting a protein called CD19 on certain immune cells can calm the disease.
This trial tests FT819, a new type of immune cell therapy (CAR T cells), for people with lupus nephritis—kidney inflammation caused by lupus—who haven't responded well to standard treatments. The goal is to see if this therapy can reduce kidney damage and improve kidney function.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.